Roche Holding AG Pre-Tax Profit Margin 2010-2024 | RHHBY

Current and historical pre-tax profit margin for Roche Holding AG (RHHBY) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Roche Holding AG pre-tax profit margin for the three months ending June 30, 2024 was .
Roche Holding AG Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $252.630B $68.726B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $826.256B 66.95
Novo Nordisk (NVO) Denmark $391.178B 26.50
Johnson & Johnson (JNJ) United States $369.594B 15.37
AbbVie (ABBV) United States $341.005B 19.07
AstraZeneca (AZN) United Kingdom $224.395B 17.61
Merck (MRK) United States $222.734B 11.52
Novartis AG (NVS) Switzerland $218.667B 13.70
Pfizer (PFE) United States $146.378B 8.31
Sanofi (SNY) $134.176B 12.71
Bayer (BAYRY) Germany $21.810B 3.49
Innoviva (INVA) United States $1.143B 9.51